Patents by Inventor Colin Peter Dell

Colin Peter Dell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists
    Patent number: 7868014
    Abstract: The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: January 11, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Colin Peter Dell, Bruce Anthony Dressman, Jason Kenneth Myers, Eric Samuel Nisenbaum
  • 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists
    Publication number: 20080300266
    Abstract: The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 13, 2005
    Publication date: December 4, 2008
    Applicant: Eli Lilly And Company
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Colin Peter Dell, Bruce Anthony Dressman, Jason Kenneth Myers, Eric Samuel Nisenbaum
  • Modulators of acetylcholine receptors
    Patent number: 7148236
    Abstract: The present invention relates to compounds that modulate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to thio-bridged aryl compounds that are capable of modulating acetylcholine receptors and pharmaceutical compositions comprising such compounds. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: December 12, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Peter Charles Astles, Stephen Richard Baker, Rowena Villanueva Cube, Jose Antonio Martinez-Perez, Ana Isabel Mateo Herranz, Jean Michel Vernier, Colin Peter Dell, Sonia Gutierrez, Lourdes Prieto, Martine Keenan, Adam Jan Sanderson, Colin William Smith
  • Pharmaceutical compounds
    Patent number: 5663375
    Abstract: Pharmaceutical compounds of the formula ##STR1## in which n is 0, 1 or 2 and R.sup.1 is attached at any of the positions 7, 8, 9 or 10, and each R.sup.1 is halo, carboxy, trifluoromethyl, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, hydroxy-C.sub.1-4 alkyl, hydroxy-C.sub.1-4 alkoxy, nitrogen-containing heterocyclyl, nitro, trifluoromethoxy, --COOR.sup.5 where R.sup.5 is an ester group, --COR.sup.6, --CONR.sup.6 R.sup.7 or --NR.sup.6 R.sup.7 where R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl;R.sup.2 is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, said phenyl, naphthyl and heteroaryl groups being optionally substituted, or R.sup.2 is furanyl optionally substituted with C.sub.1-4 alkyl;R.sup.3 is nitrile, carboxy, --COOR.sup.8 where R.sup.8 is an ester group, or --CONR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 are each hydrogen or C.sub.1-4 alkyl; andR.sup.4 is --NR.sup.11 R.sup.12, --NR.sup.11 COR.sup.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: September 2, 1997
    Assignees: Eli Lilly and Company, Lilly Industries Limited
    Inventors: Michael Brunavs, Colin Peter Dell, Peter Thaddeus Gallagher, William Martin Owton, Colin William Smith